Agios Pharma CEO Jackie Fouse to step down, as a former Alexion executive takes over

Jackie Fouse is stepping down as CEO of Agios Pharmaceuticals, replaced by Brian Goff, a former executive with Alexion Pharmaceuticals, the company announced Tuesday. Fouse will remain with Agios as its new board chairperson.

Agios is framing the management reshuffle as the latest in a series of deliberate, strategic decisions to bolster the company’s future by pivoting toward the development of drugs for genetically-defined diseases. But investors, already wary of some of the company’s recent moves, may interpret Fouse’s decision to vacate the CEO post as another sign Agios’s plan is not working.

“I view this as a terrific opportunity for me to take on a different role but stay in the Agios team after what’s been a very eventful three and a half years,” Fouse said in an interview with STAT.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In